Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

ROCHESTER, Minn., May 17, 2022 -- (Healthcare Sales & Marketing Network) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry ... Biopharmaceuticals, Oncology, Venture Capital Vyriad, oncolytic virus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news